<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<META content="MSHTML 6.00.2900.2963" name=GENERATOR>
<STYLE></STYLE>
</HEAD>
<BODY bgColor=#ffffff>
<DIV><FONT size=4>
<H2 class=inline>Taking on neglected diseases</H2>
<UL class="straptext notlist highlight colspacer">
<LI>30 September 2006 </LI>
<LI>From New Scientist Print Edition. <A
href="http://www.newscientist.com/subscribe.ns?promcode=nsarttop">Subscribe</A>
and get 4 free issues. </LI></UL></FONT></DIV>
<DIV><FONT size=4></FONT> </DIV>
<DIV>
<P>They kill millions of people each year - and get away with it. Tropical
diseases account for about 12 per cent of global sickness, yet only 1.3 per cent
of all drugs developed between 1975 and 2004 were for treating these infections.
Last week, scientists from 34 nations met in Nairobi, Kenya, to discuss the
problem.</P>
<P>"These diseases are neglected because the market-driven drug R&D system
that predominates in the developed world neglects the needs of the patients in
the developing world," says Ann-Marie Sevcsik of the Geneva-based Drugs for
Neglected Diseases initiative (DNDi). The diseases, such as sleeping sickness,
leishmaniasis and malaria, tend to affect the poorest and most powerless in
rural and deprived urban areas of developing countries.</P>
<P>At the meeting, delegates resolved to ensure that two potential drugs for
sleeping sickness enter preclinical trials by 2008, as part of broader goal to
develop six to eight new field-relevant treatments for neglected diseases by
2014. To meet these goals, support from drug companies and aid agencies will be
vital, such as the $100 million that the US Agency for International Development
last week committed to neglected diseases. However, it is also crucial to draw
on local experience, says Monique Wasunna, DNDi's Africa coordinator and chair
of the Leishmaniasis East Africa Platform.</P>
<P>"The greatest challenge to healthcare in the developing world is the ability
to develop tools of modern science that are adapted to the socioeconomic
conditions of patients in the developing world," Wasunna says. For example, DNDi
will soon distribute a new artemisinin-based drug for chloroquine-resistant
malaria that involves taking a single tablet just once every three days. Such
fixed-dosed therapies should make it much simpler to get patients to finish
their treatment.</P>
<DIV class="straptext colspacer highlight">From issue 2571 of New Scientist
magazine, 30 September 2006, page 6</DIV></DIV></BODY></HTML>